2019, Number 6
<< Back Next >>
Acta Ortop Mex 2019; 33 (6)
Use of tranexamic acid in primary total knee arthroplasty
Dobarganes-Barlow FG, López-Villers A, Trueba-Vasavilbaso C, Navarrete-Álvarez JM, Rebuelta-Cancio AA, Guevara-Álvarez A, Garcini-Munguia FA, Téllez-Hoyos S
Language: Spanish
References: 19
Page: 352-356
PDF size: 114.95 Kb.
ABSTRACT
Background: Reducing blood loss and transfusions in patients operated on primary TKR is associated with a better clinical and functional outcome. The use of Tranexamic Acid (ATX) is one of the methods used to decrease that bleeding.
Material and methods: Results in Hb, Hto, rate of bleeding and transfusion, surgical time and pain between groups A (with ATX) and group B (without tranexamic acid) after TKR are compared. Results: Statistically significant differences were found during surgery and perisurgical bleeding, in the decrease of Hb at 24 hours, transfusion rate, surgical time and pain to wandering in favor of group A.
Discussion: There are no published studies in Mexico on the use of ATX in patients operated on TKR. We consider its use to be increasingly common, the optimal dose and route of administration remains a controversial topic.
Conclusion: The use of ATX in the proposed scheme is safe and effective in reducing the rate of bleeding and transfusions in patients operated on ATR.
REFERENCES
Huang ZY, Pei FX, Ma J, Yang J, Zhou ZK, Kang PD, et al. Comparison of three different tourniquet application strategies for minimally invasive total knee arthroplasty: a prospective non-randomized clinical trial. Arch Orthop Trauma Surg. 2014; 134(4): 561-70.
Su EP, Su S. Strategies for reducing perioperative blood loss in total knee arthroplasty. Bone Joint J. 2016; 98B(1 Suppl A): 98-100.
Hart A, Khalil JA, Carli A, Huk O, Zukor D, Antoniou J. Blood transfusion in primary total hip and knee arthroplasty. Incidence, risk factors, and thirty-day complication rates. J Bone Joint Surg Am. 2014; 96(23): 1945-51.
Friedman R, Homering M, Holberg G, Berkowitz SD. Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty. J Bone Joint Surg Am. 2014; 96(4): 272-8. Available from: http://insights.ovid.com/crossref?an=00004623- 201402190-00002.
Dobarganes-Barlow F, Otero-Cámara E, Romero-Vargas S, Pérez-Frías J, Negrete-Corona J. Uso de recuperador de sangre durante la artroplastía de rodilla. Acta Ortop Mex. 2014; 28(4): 228-32. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=99329212&lang=es&si te=ehost-live.
Xie J, Ma J, Yao H, Yue C, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. J Arthroplasty. 2016; 31(11): 2458-64. Available from: http://dx.doi.org/10.1016/j.arth.2016.04.034.
Huang ZY, Ma J, Shen B, Pei FX. Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2014; 29(12): 2342-6. Available from: http://dx.doi.org/10.1016/j.arth.2014.05.026.
Xie J, Ma J, Kang P, Zhou Z, Shen B, Yang J, et al. Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases. Thromb Res]. 2015; 136(2): 234-8. Available from: http://dx.doi.org/10.1016/j.thromres.2015.05.014.
Gillette BP, Desimone LJ, Trousdale RT, Pagnano MW, Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty knee. Clin Orthop Relat Res. 2013; 471(1): 150-4.
Goldstein ZH. Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2014; 29(9): 186-8. Available from: http://dx.doi.org/10.1016/j.arth.2014.01.038.
Irwin A, Khan SK, Jameson SS, Tate RC, Copeland C, Reed MR. Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J. 2013; 95B(11): 1556-61.
Kim TK, Chang CB, Koh IJ. Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review. Knee Surg Sport Traumatol Arthrosc. 2014; 22(8): 1849-58.
Zhao-Yu C, Yan G, Wei C, Yuejv L, Ying-Ze Z. Reduced blood loss after intra-articular tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature. Knee Surg Sports Traumatol Arthrosc. 2014; 22(12): 3181-90.
Lin PC, Hsu CH, Huang CC, Chen WS, Wang JW. The blood-saving effect of tranexamic acid in minimally invasive total knee replacement: is an additional pre-operative injection effective? J Bone Joint Surg Br. 2012; 94(7): 932-6. Available from: http://www.bjj.boneandjoint.org.uk/cgi/doi/10.1302/0301-620X.94B7.28386.
Hourlier H, Reina N, Fennema P. Single dose intravenous tranexamic acid as effective as continuous infusion in primary total knee arthroplasty: a randomised clinical trial. Arch Orthop Trauma Surg. 2015; 135(4): 465-71.
Subramanyam KN, Khanchandani P, Tulajaprasad PV, Jaipuria J, Mundargi AV. Efficacy and safety of intra-articular versus intravenous tranexamic acid in reducing perioperative blood loss in total knee arthroplasty: a prospective randomized double-blind equivalence trial. Bone Joint J. 2018; 100B(2): 152-60.
Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol). 1980; 14: 41-7. Available from: http://jcp.bmj.com/cgi/doi/10.1136/jcp.s3- 14.1.41.
Jain NP, Nisthane PP, Shah NA. Combined administration of systemic and topical tranexamic acid for total knee arthroplasty: can it be a better regimen and yet safe? A randomized controlled trial. J Arthroplasty. 2016; 31(2): 542-7. Available from: http://dx.doi.org/10.1016/j.arth.2015.09.029.
Nielsen CS, Jans Ø, Ørsnes T, Foss NB, Troelsen A, Husted H. Combined intra-articular and intravenous tranexamic acid reduces blood loss in total knee arthroplasty. J Bone Jointt Surg Am. 2016; 98(10): 835-41. Available from: http://insights.ovid.com/crossref?an=00004623-201605180-00005.